Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.95 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446047 | 1.00 | DGAT1 (0.95) | DGAT1EPHX2LMNARAB9A | |
| SCHEMBL4885327 | 0.98 | DGAT1 (1.00) | DGAT1EPHX2 | |
| SCHEMBL4892004 | 0.89 | DGAT1 (0.96) | DGAT1EPHX2RAB9A | |
| SCHEMBL5364648 | 0.89 | DGAT1 (0.96) | DGAT1EPHX2RAB9A | |
| SCHEMBL4898766 | 0.87 | DGAT1 (0.74) | DGAT1EPHX2 | |
| SCHEMBL4890955 | 0.87 | DGAT1 (1.00) | DGAT1EPHX2RAB9A | |
| SCHEMBL4890900 | 0.86 | DGAT1 (0.77) | DGAT1LMNARAB9A | |
| SCHEMBL4890035 | 0.86 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL4786124 | 0.86 | DGAT1 (0.70) | DGAT1LMNA | |
| SCHEMBL4741529 | 0.86 | DGAT1 (0.70) | DGAT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007137103-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, LCAT | DGAT1 1/4885EPHX2 1371/4885LMNA 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.